Gabapentin and Eosinophilic bronchitis - a phase IV clinical study of FDA data


Eosinophilic bronchitis is found among people who take Gabapentin, especially for people who are male, 50-59 old.

The phase IV clinical study analyzes which people take Gabapentin and have Eosinophilic bronchitis. It is created by eHealthMe based on reports of 237,304 people who have side effects when taking Gabapentin from the FDA, and is updated regularly. You can use the study as a second opinion to make health care decisions.

With medical big data and AI algorithms, eHealthMe enables everyone to run phase IV clinical trial to detect adverse drug outcomes and monitor effectiveness. Our original studies have been referenced on 600+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Most recently, phase IV clinial trails for COVID 19 vaccines have been added, check here.

On Jul, 04, 2022

237,304 people reported to have side effects when taking Gabapentin.
Among them, 6 people (0.0%) have Eosinophilic bronchitis.

What is Gabapentin?

Gabapentin has active ingredients of gabapentin. It is often used in neuralgia. eHealthMe is studying from 245,414 Gabapentin users for its effectiveness, alternative drugs and more.

What is Eosinophilic bronchitis?

Eosinophilic bronchitis (a special type of inflammation in the airways) is found to be associated with 33 drugs and 11 conditions by eHealthMe.

Number of Gabapentin and Eosinophilic bronchitis reports submitted per year:

Could Gabapentin cause Eosinophilic bronchitis?

Gender of people who have Eosinophilic bronchitis when taking Gabapentin *:

  • female: 0.0 %
  • male: 100 %

Age of people who have Eosinophilic bronchitis when taking Gabapentin *:

  • 0-1: 0.0 %
  • 2-9: 0.0 %
  • 10-19: 0.0 %
  • 20-29: 0.0 %
  • 30-39: 0.0 %
  • 40-49: 0.0 %
  • 50-59: 100 %
  • 60+: 0.0 %

Common drugs people take besides Gabapentin *:

  1. Xarelto: 6 people, 100.00%
  2. Calcium: 6 people, 100.00%
  3. Vitamin D: 3 people, 50.00%
  4. Nucala: 3 people, 50.00%
  5. Imuran: 3 people, 50.00%
  6. Breo Ellipta: 3 people, 50.00%
  7. Arava: 3 people, 50.00%
  8. Flovent: 2 people, 33.33%
  9. Crestor: 2 people, 33.33%

Common side effects people have besides Eosinophilic bronchitis *:

  1. Weight Decreased: 6 people, 100.00%
  2. Polyp: 6 people, 100.00%
  3. Hypoaesthesia (reduced sense of touch or sensation): 6 people, 100.00%
  4. Enterocolitis (inflammation of the digestive tract, involving enteritis of the small intestine and colitis of the colon): 6 people, 100.00%
  5. Enteritis (inflammation of the small intestine): 6 people, 100.00%
  6. Disease Recurrence: 6 people, 100.00%
  7. Diarrhea: 6 people, 100.00%
  8. Arthritis (form of joint disorder that involves inflammation of one or more joints): 6 people, 100.00%
  9. Abdominal Pain: 6 people, 100.00%
  10. Sinusitis (inflammation of sinus): 3 people, 50.00%

* Approximation only. Some reports may have incomplete information.

Do you take Gabapentin and have Eosinophilic bronchitis?

Check whether Eosinophilic bronchitis is associated with a drug or a condition

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.

Related publications that referenced our studies

Related studies

Alternative drugs to, pros and cons of Gabapentin:

Eosinophilic bronchitis treatments and more:

COVID vaccines that are related to Eosinophilic bronchitis:

How severe was Eosinophilic bronchitis and when was it recovered:

Expand to all the drugs that have ingredients of gabapentin:

Common drugs associated with Eosinophilic bronchitis:

All the drugs that are associated with Eosinophilic bronchitis:

All the conditions that are associated with Eosinophilic bronchitis:

How the study uses the data?

The study uses data from the FDA. It is based on gabapentin (the active ingredients of Gabapentin) and Gabapentin (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).


WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe: